Ex vivo delta opioid receptor autoradiography: CNS receptor occupancy of two novel compounds over their antihyperalgesic dose range

被引:6
作者
Codd, Ellen E. [1 ]
Ma, Jianya [1 ]
Zhang, Sui-Po [1 ]
Stone, Dennis J., Jr. [1 ]
Colburn, Raymond W. [1 ]
Brandt, Michael R. [1 ]
Chevalier, Kristen M. [1 ]
Zhu, Yongxin [1 ]
Peng, Sean [1 ]
Cai, Chaozhong [1 ]
Acton, Paul D. [1 ]
Flores, Christopher M. [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev LLC, Drug Discovery, Spring House, PA 19477 USA
关键词
Delta opioid agonist; Hyperalgesia; Ex vivo autoradiography; CFA thermal hyperalgesia; Receptor occupancy; PAIN; MU; PHARMACOKINETICS; TRAFFICKING; AGONISTS; POTENT; MODEL;
D O I
10.1016/j.pbb.2010.04.020
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Discovered as part of an effort to identify delta opioid (DOPr or DOR) agonist analgesics. JNJ-20788560 and JNJ-39204880 exhibited high DOR affinity, with K-i values of 1.7 and 2.0 nM, respectively, and were selective for DOR over the mu opioid receptor (MOPr or MOR), with 596- and 122-fold selectivity, respectively. Both compounds stimulated DOR but not MOR induced GTP gamma S binding and were effective antihyperalgesic agents in the complete Freund's adjuvant model of thermal hyperalgesia in the rat, with oral ED50 values of 13.5 and 35 mg/kg, corresponding to plasma levels of 1 and 9 mu M. respectively. Autoradiographic analysis of DOR and MOR occupancy in sections of brain (striatum) and lumbar spinal cord (L4-L6) was determined ex vivo. using radiolabeled naltrindole or DAMGO. Quantitative image analysis resulted in striatal DOR ED50 values of 6.9 and 10.7 mg/kg, for JNJ-20788560 and JNJ-39204880 respectively, and spinal cord values of 6.4 and 32 mg/kg, respectively. Neither compound dose-dependently occupied MOR within the dose range studied. Thus, this study confirmed the DOR selectively over MOR of both compounds following their oral administration, and further demonstrated dose-dependent DOR occupancy by each compound across its antihyperalgesic dose range. Importantly, these in vitro, in vivo, and ex vivo data revealed that the greater in vitro potency of JNJ-20788560 was paralleled by its greater in vivo potency, although JNJ-39204880 achieved higher plasma levels following its oral administration. The receptor occupancy levels observed at the pharmacologic ED50 doses of these compounds suggest the need for greater target engagement by JNJ-39204880 than by JNJ-20788560 to elicit a similar therapeutic response. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:130 / 135
页数:6
相关论文
共 18 条
[1]   Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations [J].
Brooks, TA ;
Hawkins, BT ;
Huber, JD ;
Egleton, RD ;
Davis, TP .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2005, 289 (02) :H738-H743
[2]   Trafficking of δ-opioid receptors and other G-protein-coupled receptors:: implications for pain and analgesia [J].
Cahill, Catherine M. ;
Holdridge, Sarah V. ;
Morinville, Anne .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (01) :23-31
[3]   Up-regulation and trafficking of δ opioid receptor in a model of chronic inflammation:: implications for pain control [J].
Cahill, CM ;
Morinville, A ;
Hoffert, C ;
O'Donnell, D ;
Beaudet, A .
PAIN, 2003, 101 (1-2) :199-208
[4]   The novel, orally active, delta opioid RWJ-394674 is biotransformed to the potent Mu opioid RWJ-413216 [J].
Codd, E. E. ;
Carson, J. R. ;
Colburn, R. W. ;
Dax, S. L. ;
Desai-Krieger, D. ;
Martinez, R. P. ;
McKown, L. A. ;
Neilson, L. A. ;
Pitis, P. M. ;
Stahle, P. L. ;
Stone, D. J. ;
Streeter, A. J. ;
Wu, W. N. ;
Zhang, S. P. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (03) :1273-1279
[5]   JNJ-20788560 [9-(8-Azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic Acid Diethylamide], a Selective Delta Opioid Receptor Agonist, Is a Potent and Efficacious Antihyperalgesic Agent That Does Not Produce Respiratory Depression, Pharmacologic Tolerance, or Physical Dependence [J].
Codd, Ellen E. ;
Carson, John R. ;
Colburn, Raymond W. ;
Stone, Dennis J. ;
Van Besien, Christopher R. ;
Zhang, Sui-Po ;
Wade, Paul R. ;
Gallantine, Elizabeth L. ;
Meert, Theo F. ;
Molino, Lory ;
Pullan, Shirley ;
Razler, Christine M. ;
Dax, Scott L. ;
Flores, Christopher M. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 329 (01) :241-251
[6]   Antihyperalgesic effects of δ opioid agonists in a rat model of chronic inflammation [J].
Fraser, GL ;
Gaudreau, GA ;
Clarke, PBS ;
Ménard, DP ;
Perkins, MN .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (08) :1668-1672
[7]   A NEW AND SENSITIVE METHOD FOR MEASURING THERMAL NOCICEPTION IN CUTANEOUS HYPERALGESIA [J].
HARGREAVES, K ;
DUBNER, R ;
BROWN, F ;
FLORES, C ;
JORIS, J .
PAIN, 1988, 32 (01) :77-88
[8]   Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression [J].
Huber, JD ;
Witt, KA ;
Hom, S ;
Egleton, RD ;
Mark, KS ;
Davis, TP .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 280 (03) :H1241-H1248
[9]   Hepatic pharmacokinetics of propranolol in rats with adjuvant-induced systemic inflammation [J].
Hung, DY ;
Siebert, GA ;
Chang, P ;
Whitehouse, MW ;
Fletcher, L ;
Crawford, DHG ;
Roberts, MS .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2006, 290 (02) :G343-G351
[10]  
Hurley RW, 1999, J PHARMACOL EXP THER, V289, P993